Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry

Adrian Robert Hunt; null Vuong Nguyen; Jennifer J. Arnold; Ian L. McAllister; Hemal Mehta; Alessandro Invernizzi; Theodorus Ponsioen; Pierre-Henry Gabrielle; Louise O'Toole; Pavol Kusenda; Socorro Alforja; Daniel Barthelmes; Mark C. Gillies

doi:10.1136/bjophthalmol-2021-320482

Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry

Adrian Robert Hunt, Vuong Nguyen, Jennifer J. Arnold, Ian L. McAllister, Hemal Mehta, Alessandro Invernizzi, Theodorus Ponsioen, Pierre-Henry Gabrielle, Louise O'Toole, Pavol Kusenda, Socorro Alforja, Daniel Barthelmes, Mark C. Gillies

Centre for Ophthalmology and Visual Science (affiliated with the Lions Eye Institute)

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Background/aims To describe baseline characteristics and 12-month outcomes with vascular endothelial growth factor (VEGF) inhibitors of treatment-naive hemiretinal vein occlusion (HRVO) compared with branch (BRVO) and central (CRVO) variants in routine clinical care. Methods A database observational study recruited 79 HRVO eyes, 590 BRVO eyes and 344 CRVO eyes that initiated therapy over 10 years. The primary outcome was mean change in visual acuity (VA-letters read on a logarithm of minimal angle of resolution chart) at 12 months. Secondary outcomes included mean change in central subfield thickness (CST), injections and visits. Results At baseline, mean VA in HRVO (53.8) was similar to CRVO (51.9; p=0.40) but lower than BRVO (59.4; p=0.009). HRVO eyes improved to match BRVO eyes from soon after treatment started through 12 months. Mean change in VA was greater in HRVO (+16.4) than both BRVO (+11.4; p=0.006) and CRVO (+8.5; p

Original language	English
Article number	bjophthalmol-2021-320482
Pages (from-to)	842-848
Number of pages	7
Journal	British Journal of Ophthalmology
Volume	107
Issue number	6
DOIs	https://doi.org/10.1136/bjophthalmol-2021-320482
Publication status	Published - 2022

Access to Document

10.1136/bjophthalmol-2021-320482Licence: CC BY-NC

Cite this

Hunt, A. R., Vuong Nguyen, Arnold, J. J., McAllister, I. L., Mehta, H., Invernizzi, A., Ponsioen, T., Gabrielle, P.-H., O'Toole, L., Kusenda, P., Alforja, S., Barthelmes, D., & Gillies, M. C. (2022). Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry. British Journal of Ophthalmology, 107(6), 842-848. Article bjophthalmol-2021-320482. https://doi.org/10.1136/bjophthalmol-2021-320482

@article{99dbca2fb4f948b9a4871936746fc4b2,

title = "Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry",

abstract = "Background/aims To describe baseline characteristics and 12-month outcomes with vascular endothelial growth factor (VEGF) inhibitors of treatment-naive hemiretinal vein occlusion (HRVO) compared with branch (BRVO) and central (CRVO) variants in routine clinical care. Methods A database observational study recruited 79 HRVO eyes, 590 BRVO eyes and 344 CRVO eyes that initiated therapy over 10 years. The primary outcome was mean change in visual acuity (VA-letters read on a logarithm of minimal angle of resolution chart) at 12 months. Secondary outcomes included mean change in central subfield thickness (CST), injections and visits. Results At baseline, mean VA in HRVO (53.8) was similar to CRVO (51.9; p=0.40) but lower than BRVO (59.4; p=0.009). HRVO eyes improved to match BRVO eyes from soon after treatment started through 12 months. Mean change in VA was greater in HRVO (+16.4) than both BRVO (+11.4; p=0.006) and CRVO (+8.5; p",

keywords = "macula, pharmacology, retina, treatment medical, vision, INTRAVITREAL AFLIBERCEPT INJECTION, MACULAR EDEMA SECONDARY, SUSTAINED BENEFITS, CLINICAL-FEATURES, RANIBIZUMAB, PATHOGENESIS, BEVACIZUMAB",

author = "Hunt, {Adrian Robert} and {Vuong Nguyen} and Arnold, {Jennifer J.} and McAllister, {Ian L.} and Hemal Mehta and Alessandro Invernizzi and Theodorus Ponsioen and Pierre-Henry Gabrielle and Louise O'Toole and Pavol Kusenda and Socorro Alforja and Daniel Barthelmes and Gillies, {Mark C.}",

year = "2022",

doi = "10.1136/bjophthalmol-2021-320482",

language = "English",

volume = "107",

pages = "842--848",

journal = "British Journal of Ophthalmology",

issn = "0007-1161",

publisher = "BRITISH MED JOURNAL PUBL GROUP",

number = "6",

}

Hunt, AR, Vuong Nguyen, Arnold, JJ, McAllister, IL, Mehta, H, Invernizzi, A, Ponsioen, T, Gabrielle, P-H, O'Toole, L, Kusenda, P, Alforja, S, Barthelmes, D & Gillies, MC 2022, 'Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry', British Journal of Ophthalmology, vol. 107, no. 6, bjophthalmol-2021-320482, pp. 842-848. https://doi.org/10.1136/bjophthalmol-2021-320482

Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry. / Hunt, Adrian Robert; Vuong Nguyen; Arnold, Jennifer J. et al.
In: British Journal of Ophthalmology, Vol. 107, No. 6, bjophthalmol-2021-320482, 2022, p. 842-848.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors

T2 - data from the Fight Retinal Blindness! Registry

AU - Hunt, Adrian Robert

AU - Vuong Nguyen, null

AU - Arnold, Jennifer J.

AU - McAllister, Ian L.

AU - Mehta, Hemal

AU - Invernizzi, Alessandro

AU - Ponsioen, Theodorus

AU - Gabrielle, Pierre-Henry

AU - O'Toole, Louise

AU - Kusenda, Pavol

AU - Alforja, Socorro

AU - Barthelmes, Daniel

AU - Gillies, Mark C.

PY - 2022

Y1 - 2022

N2 - Background/aims To describe baseline characteristics and 12-month outcomes with vascular endothelial growth factor (VEGF) inhibitors of treatment-naive hemiretinal vein occlusion (HRVO) compared with branch (BRVO) and central (CRVO) variants in routine clinical care. Methods A database observational study recruited 79 HRVO eyes, 590 BRVO eyes and 344 CRVO eyes that initiated therapy over 10 years. The primary outcome was mean change in visual acuity (VA-letters read on a logarithm of minimal angle of resolution chart) at 12 months. Secondary outcomes included mean change in central subfield thickness (CST), injections and visits. Results At baseline, mean VA in HRVO (53.8) was similar to CRVO (51.9; p=0.40) but lower than BRVO (59.4; p=0.009). HRVO eyes improved to match BRVO eyes from soon after treatment started through 12 months. Mean change in VA was greater in HRVO (+16.4) than both BRVO (+11.4; p=0.006) and CRVO (+8.5; p

AB - Background/aims To describe baseline characteristics and 12-month outcomes with vascular endothelial growth factor (VEGF) inhibitors of treatment-naive hemiretinal vein occlusion (HRVO) compared with branch (BRVO) and central (CRVO) variants in routine clinical care. Methods A database observational study recruited 79 HRVO eyes, 590 BRVO eyes and 344 CRVO eyes that initiated therapy over 10 years. The primary outcome was mean change in visual acuity (VA-letters read on a logarithm of minimal angle of resolution chart) at 12 months. Secondary outcomes included mean change in central subfield thickness (CST), injections and visits. Results At baseline, mean VA in HRVO (53.8) was similar to CRVO (51.9; p=0.40) but lower than BRVO (59.4; p=0.009). HRVO eyes improved to match BRVO eyes from soon after treatment started through 12 months. Mean change in VA was greater in HRVO (+16.4) than both BRVO (+11.4; p=0.006) and CRVO (+8.5; p

KW - macula

KW - pharmacology

KW - retina

KW - treatment medical

KW - vision

KW - INTRAVITREAL AFLIBERCEPT INJECTION

KW - MACULAR EDEMA SECONDARY

KW - SUSTAINED BENEFITS

KW - CLINICAL-FEATURES

KW - RANIBIZUMAB

KW - PATHOGENESIS

KW - BEVACIZUMAB

UR - http://www.scopus.com/inward/record.url?scp=85135511202&partnerID=8YFLogxK

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000748644300001

U2 - 10.1136/bjophthalmol-2021-320482

DO - 10.1136/bjophthalmol-2021-320482

M3 - Article

C2 - 35078771

SN - 0007-1161

VL - 107

SP - 842

EP - 848

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

IS - 6

M1 - bjophthalmol-2021-320482

ER -

Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry

Abstract

Access to Document

Other files and links

Fingerprint

Cite this